LGLinda Glowacki

Linda Glowacki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Linda Glowacki has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Detection of the novel synthetic opioid 2-naphthyl U-47700 (β-U10) in a series of heroin-related fatalities in Victoria, Australia

    by Lachlan Scully, Matthew Di Rago, Olaf H. Drummer, Joanna Glengarry, Kerryn Crump, Linda Glowacki, Dimitri Gerostamoulos

  • Odds of culpability associated with the presence of drugs in injured drivers

    by Olaf H. Drummer, Matthew Di Rago, Carla Morris, Gemma Wynd, Linda Glowacki, Noel W. Woodford, Dimitri Gerostamoulos

  • Open Access

    Detection of Nitazenes (2-Benzylbenzimidazoles)—Novel Synthetic Opioids in Coronial Casework in Victoria, Australia

    by Lachlan Scully, Jared W. Castle, Matthew Di Rago, Hans H. de Boer, Jennifer Schumann, Kerryn Crump, Linda Glowacki, Dimitri Gerostamoulos

    Background: The 2-benzylbenzimidazoles or nitazenes are an evolving class of highly potent mu-opioid receptor agonists. Nitazenes were originally developed in the late 1950s for pharmaceutical use as analgesics; however, due to their extreme potency and the risk of adverse health outcomes, pharmaceutical research was discontinued. Since 2019, nitazenes have emerged as illicit drugs of abuse, causing significant concern. From 2021, they have been detected in both coronial and clinical casework in Victoria, Australia. This study examined nitazene-related coronial casework in Victoria from 2021 to 2025 to explore the trends and characteristics of nitazene-related deaths. Methods: Relevant cases were identified from the Victorian Institute of Forensic Medicine’s (VIFM’s) case management system. Data were collated and analysed from all coronial cases where a nitazene was detected by a toxicological analysis between 1 January 2021 and 31 December 2025. Trend comparisons were made with nitazene detections reported in other countries. Results: Nitazenes were detected in 23 deaths from a total of approximately 33,108 coronial cases admitted to the VIFM for investigation over the time period. The age range was 17–45 years, with a median of 32 and with 87% of the deaths being male. The nitazenes detected were protonitazene (n = 14), metonitazene (n = 5), isotonitazene (n = 2), N-pyrrolidino etonitazene (n = 2), N-desethyl isotonitazene (n = 1), methylenedioxynitazene (n = 1) and etodesnitazene (n = 1). Two cases contained more than one nitazene; both involved protonitazene, one involved metonitazene, and the other involved N-desethyl isotonitazene and methylenedioxynitazene. The timeline of detection of these nitazenes displays similarities with emergence trends in other countries. The nitazene concentrations ranged from 0.1 to 33 ng/mL. Broad polydrug usage was evident in all cases, with other drugs co-detected in the blood including stimulants (particularly, methylamphetamine (48%) and cocaine (44%)) as well as pharmaceutical benzodiazepines (43%) and pharmaceutical opioids (22%), and 13% had 6-monoacetylmorphine detected in either blood or urine. Novel benzodiazepines (39%) were also common, including bromazolam, which was co-detected in 35% of cases. Nineteen deaths were attributed solely to nitazene-related mixed-drug toxicity, while the remaining four cases were attributed to cardiac- and pulmonary-related disease, with polydrug use deemed a contributing factor. Conclusions: This novel case series adds comprehensive toxicological information to the body of evidence reinforcing the high risk of harm associated with the use of nitazenes. It is imperative that toxicology services continue to monitor for nitazenes to promote community awareness against nitazene-related harm.

  • Open Access

    Estimates of crash risk associated with the presence of drugs in injured drivers

    by Olaf Drummer, Matthew Di Rago, Carla Morris, Gemma Wynd, Linda Glowacki, Noel W. Woodford, Dimitri Gerostamoulos

    Responsibility analysis was conducted on almost 10,000 drivers injured over a 10-year period in Victoria as a result of a vehicular collision and in whom comprehensive toxicology testing in blood was conducted. Multivariable logistic regression models were fitted to compute unadjusted (OR) and adjusted odds ratios (aOR). In the multivariable model, adjustments were made for gender, age group, vehicle type, and whether the crash occurred in metropolitan or rural areas. The psychoactive drug-free driver was the reference group. Drivers with ethanol (alcohol) present at any concentration (>0.01% BAC) confirmed the well-known large increases in crash risk that occur with rising blood ethanol concentration, with an aOR of 16.4 (95%CI 11.1–24.2). Drivers positive to methamphetamine and no other psychoactive drug also showed a large increase in the odds of culpability (aOR 17.2, 95%CI 10.2-29.2). Drivers with Δ9-tetrahydrocannabinol (THC) in blood showed a modest increase in odds when all concentrations (> 1ng/mL) were assessed (aOR 1.5, 95%CI 1.1-2.0) that increased to an aOR 2.1 (95%CI 0.9-4.9) when concentrations were 10 ng/mL or higher. Benzodiazepines in drivers also showed a significant increase in odds (aOR1.8, 95%CI 1.2-2.8), as well as antidepressants (aOR 1.3, 95%CI 1.0-1.6). Opioids such as codeine and oxycodone showed no measurable increase in crash risk, whereas combinations of ethanol with methamphetamine or THC gave aOR of 22.6 (95%CI 3.0-168) and 20.0 (95%CI 7.3-54.5), respectively, as well as drivers positive to both THC and methamphetamine (aOR 14.6, 95% CI 5.9-36.4). Drivers positive to one or more illicit drug, or a larger selection of psychoactive drugs in the absence of ethanol both gave similarly large increase in odds (aOR 4.0, 95%CI 3.3-5.0). This study contributes to a better understanding of risks associated with driving in the presence of common psychoactive drugs.

  • Deaths involving novel benzodiazepines in Victoria, Australia from 2018 to 2022

    by Olaf H Drummer, Samantha Joubert, Matthew Di Rago, Jared W Castle, Kerryn Crump, Linda Glowacki, Dimitri Gerostamoulos

    Novel benzodiazepine (NBz) detections in Victorian coronial cases started early in 2018 and have continued to increase in number and type up to December 2022. The 11 different NBz detections included etizolam (n = 82), flualprazolam (n = 43), clonazolam or 8-aminoclonazolam (n = 30), bromazolam (n = 15), clobromazolam (n = 13), phenazepam (n = 13), flubromazolam (n = 12), flubromazepam (n = 8), desalkylflurazepam (n = 6), diclazepam (n = 2), and estazolam (n = 1). The pattern of detections varied over the 5-year period, with different compounds appearing over different time frames. The most recent NBz to appear were bromazolam, clobromazolam, flubromazepam, and phenazepam, whereas etizolam had been seen regularly in case work since 2018. Of the total 133 deaths, 95 were considered drug-related deaths by forensic pathologists with at least one additional CNS depressant also present capable of contributing to death. All deaths involved other (non-benzodiazepine) CNS active drugs, although many involved multiple NBz, with five or more different benzodiazepines detected in eight cases.


  • Identification of clobromazolam in Australian emergency department intoxications using data-independent high-resolution mass spectrometry and the HighResNPS.com database

    by Jared W Castle, Rebekka Syrjanen, Matthew Di Rago, Jennifer L Schumann, Shaun L Greene, Linda L Glowacki, Dimitri Gerostamoulos

    The proliferation of novel psychoactive substances (NPSs) continues to challenge toxicology laboratories. In particular, the United Nations Office on Drugs and Crime considers designer benzodiazepines to be a current primary threat among all NPSs. Herein, we report detection of a new emerging designer benzodiazepine, clobromazolam, using high-resolution mass spectrometry and untargeted data acquisition in combination with a “suspect screening” method built from the crowd-sourced HighResNPS.com database. Our laboratory first detected clobromazolam in emergency department presenting intoxications included within the Emerging Drugs Network of Australia—Victoria project in the state of Victoria, Australia, from April 2022 to March 2023. Clobromazolam was the most frequent designer benzodiazepine detected in this cohort (100/993 cases, 10%). No patients reported intentional administration of clobromazolam, although over half reported exposure to alprazolam, which was detected in only 7% of cases. Polydrug use was prevalent (98%), with phenazepam (45%), methylamphetamine (71%) and other benzodiazepines (60%) most frequently co-detected. This is the first case series published in the literature concerning clobromazolam in clinical patients. The identification of clobromazolam in patients presenting to emergency departments in Victoria demonstrates how high-resolution mass spectrometry coupled with the HighResNPS.com database can be a valuable tool to assist toxicology laboratories in keeping abreast of emerging psychoactive drug use.


  • Open Access

    Quantitative analysis of tetrahydrocannabinol isomers and other toxicologically relevant drugs in blood

    by Dylan Mantinieks, Matthew Di Rago, Olaf H. Drummer, Linda Glowacki, Jennifer Schumann, Dimitri Gerostamoulos

    A multi‐analyte liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) method is described, involving the separation of delta‐9‐tetrahydrocannabinol (delta‐9‐THC) and delta‐8‐THC in addition to other commonly encountered drugs and metabolites. Briefly, sample preparation involved an alkaline liquid–liquid extraction (methyl tert‐butyl ether) of blood (100 μl). The solvent layer was transferred, evaporated to dryness, reconstituted, and samples then separated on an Agilent Poroshell 120 EC‐C18 100 Å (50 mm × 3.0 mm, 2.7 μm) analytical column using a multi‐step gradient elution of 50 mM ammonium formate in water (pH 3.5) and 0.1% formic acid in methanol over 14 min. A SCIEX Triple Quad 6500+ system operating in scheduled multiple reaction monitoring and positive electrospray ionization was used for detection. There were no interferences, and matrix effects were generally acceptable (±20% of neat response). Linearity was achieved within the calibration range, including methylamphetamine (MA) (10–1000 ng/ml), 3,4‐methylenedioxy‐N‐methylamphetamine (MDMA) (10–1,000 ng/ml), cocaine (10–1000 ng/ml), and two THC isomers (1–100 ng/ml). Accuracies of MA, MDMA, cocaine, and two THC isomers were 3.6 to 8.9%, −1.2 to 4%, −5.3 to 5.8%, and −11 to 14%, respectively; while precision estimates of the same were 1.6 to 5.4%, 1.7 to 5.3%, 1.2 to 4.5%, and 2 to 10%, respectively. Autosampler stability and dilution integrity were within acceptable limits, and no carryover was detected at the limit of detection. This validated LC‐MS/MS method made the routine identification of both delta‐9‐THC and delta‐8‐THC in blood possible.


  • Fatal Intoxications from a Combination of 4-Fluoroamphetamine and 25C-NBOMe

    by Dimitri Gerostamoulos, Linda Glowacki, Maria Pricone, Kerryn Crump, Matthew Di Rago, Samantha Joubert, Matthew J Lynch, Noel W Woodford, Olaf H Drummer

    Six fatalities have occurred from the ingestion of a combination of new psychoactive substances (NPSs), 4-fluoroamphetamine (4FA) and 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) over a 9-month period. Four of these fatalities (one older female and three young males) were from direct adverse effects of drugs, and one each from a fall while being intoxicated and during restraint. All cases were subject to full postmortem examinations that included collection of femoral blood. The four drug-caused fatalities had postmortem blood concentrations for 4FA and 25C-NBOMe of 330–682 ng/L (median 417) and 1.4–12 ng/mL (median 4.3), respectively. The other two cases (both young males) where death was considered to have been caused indirectly by drug intoxication had 4FA and 25C-NBOMe postmortem concentrations of 21 and 123 ng/mL, and 1.8 and 4.5 ng/mL, respectively. None of these cases showed concentrations of drugs that suggested use of high recreational doses. In one drug-caused death, capsules and a brown powder obtained from the scene were found to contain a mixture of these two NPSs. With the exception of one drug-caused death, other drugs were detected; however, the effects of the two NPSs together were regarded as the primary triggers for the deaths. There were no consistent symptoms or pathology in these cases; however, agitation/aggression was observed in two cases prior to their collapse, with seizures in possibly three cases. Pulmonary and/or cerebral edema was noted in three cases. Potentially significant natural disease (a mildly enlarged heart) was only observed in one drug-caused case. These cases illustrate a possible increased risk of sudden death with this combination of drugs, both of which can elevate serotonin concentrations as well as act as strong stimulants. These cases also illustrate the difficulty in detecting NPS in cases where no prior information is available that might suggest their use.


  • Open Access

    Postmortem Metabolomics: Strategies to Assess Time-Dependent Postmortem Changes of Diazepam, Nordiazepam, Morphine, Codeine, Mirtazapine and Citalopram

    by Lana Brockbals, Yannick Wartmann, Dylan Mantinieks, Linda L. Glowacki, Dimitri Gerostamoulos, Thomas Kraemer, Andrea E. Steuer

    Postmortem redistribution (PMR) can result in artificial drug concentration changes following death and complicate forensic case interpretation. Currently, no accurate methods for PMR prediction exist. Hence, alternative strategies were developed investigating the time-dependent postmortem behavior of diazepam, nordiazepam, morphine, codeine, mirtazapine and citalopram. For 477 authentic postmortem cases, femoral blood samples were collected at two postmortem time-points. All samples were quantified for drugs of abuse (targeted; liquid chromatography-tandem mass spectrometry LC-MS/MS) and characterized for small endogenous molecules (untargeted; gas chromatography-high resolution MS (GC-HRMS). Trends for significant time-dependent concentration decreases (diazepam (n = 137), nordiazepam (n = 126)), increases (mirtazapine (n = 55), citalopram (n = 50)) or minimal median postmortem changes (morphine (n = 122), codeine (n = 92)) could be observed. Robust mathematical mixed effect models were created for the generalized postmortem behavior of diazepam and nordiazepam, which could be used to back-calculate drug concentrations towards a time-point closer to the estimated time of death (caution: inter-individual variability). Significant correlations between time-dependent concentration changes of morphine, mirtazapine and citalopram with individual endogenous molecules could be determined; no correlation was deemed strong enough for successful a posteriori estimation on the occurrence of PMR for specific cases. The current dataset did successfully lead to a significant knowledge gain in further understanding the time-dependent postmortem behavior of the studied drugs (of abuse).